Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F24%3A10474998" target="_blank" >RIV/00064203:_____/24:10474998 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/24:10474998
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=T7zVg.DN6-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=T7zVg.DN6-</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2023012109" target="_blank" >10.1182/bloodadvances.2023012109</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?
Popis výsledku v původním jazyce
Since 2022 large B-cell lymphoma with IRF4-rearrangment (LBCL-IRF4+) has been recognized as a definite entity by the World Health Organization (WHO) classification of hematolymphoid tumors. It is characterized by a follicular and/or diffuse growth pattern as well as a strong expression of IRF4, which is due to translocation of IRF4 with an immunoglobulin gene. Essential and desirable diagnostic criteria are set by the WHO including clinical, morphological, immunophenotypical and molecular- genetic parameters. Given that most LBCL-IRF4+ patients are children and young people, the rarity of this lymphoma and lack of any prospective trials, most data on LBCL-IRF4+ come from small reports. Thus, two of the largest childhood non-Hodgkin lymphoma (NHL) consortia, the European Intergroup for Childhood NHL (eicnhl) and the international Berlin-Frankfurt-Münster (i-BFM) Group, designed a retrospective multinational study of LBCL-IRF4+ in children and young people. Here we present data from this series, the largest reported to date.
Název v anglickém jazyce
Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?
Popis výsledku anglicky
Since 2022 large B-cell lymphoma with IRF4-rearrangment (LBCL-IRF4+) has been recognized as a definite entity by the World Health Organization (WHO) classification of hematolymphoid tumors. It is characterized by a follicular and/or diffuse growth pattern as well as a strong expression of IRF4, which is due to translocation of IRF4 with an immunoglobulin gene. Essential and desirable diagnostic criteria are set by the WHO including clinical, morphological, immunophenotypical and molecular- genetic parameters. Given that most LBCL-IRF4+ patients are children and young people, the rarity of this lymphoma and lack of any prospective trials, most data on LBCL-IRF4+ come from small reports. Thus, two of the largest childhood non-Hodgkin lymphoma (NHL) consortia, the European Intergroup for Childhood NHL (eicnhl) and the international Berlin-Frankfurt-Münster (i-BFM) Group, designed a retrospective multinational study of LBCL-IRF4+ in children and young people. Here we present data from this series, the largest reported to date.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2024
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Blood Advances
ISSN
2473-9529
e-ISSN
2473-9537
Svazek periodika
8
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
6
Strana od-do
1509-1514
Kód UT WoS článku
001214951700001
EID výsledku v databázi Scopus
2-s2.0-85188738515